CardioVascular and Interventional Radiology (CVIR) is an official journal of
Founded in 1978 by Professors Herbert L. Abrams and Eberhard Zeitler,
CVIR is the longest-running journal in the field of vascular and interventional radiology.
CIRSE Members have unlimited online access to all CVIR articles. To access the full text articles, log in with the credentials for myCIRSE.
Prof. Klaus Hausegger's and Prof. Jim Reekers' terms of office as CVIR and CVIR Endovascular Editor-in-Chief, respectively, will come to an end in 2025. Therefore, CIRSE has launched a call for applications to fill these positions, as well as the position of editor-in-chief of its soon to be launched journal CVIR Oncology (planned to start accepting submissions in 2025). Each of the three positions is for a four-year term beginning in 2025.
Find out more here and make sure to submit your application by March 4!
Endoleaks represent the most common complication after EVAR. Some types are associated with ongoing risk of aneurysm rupture and necessitate long-term surveillance and secondary interventions, and this SOP provides up-to-date recommendations for its safe performance.
Optimize your article with the new feature in CVIR! Submit a visual abstract of your paper in addition to the textual abstract, to highlight your research and findings. All article types are eligible, with the exception of editorials, letters to the editor and commentaries. Click here to download the template.
We are happy to announce CVIR’s 2022 impact factor which increased to 2.9! This achievement underscores the exceptional quality and importance of the articles published in the journal. A big thank you to the journal’s dedicated authors, reviewers, editors, and readers for their invaluable contributions and support.
CVIR’s November issue features a special section on MSK interventions curated by world-renown expert in the field: Julien Garnon.
This special section presents the latest technical advancements and most significant data from the literature on hot topics in MSK. The goal is to give any IR an overview of what is feasible and for which result.
The benefit of the ‘halo’: Read the outcomes of the long-term results of this single centre prospective study on 130 patients that underwent treatment with paclitaxel eluting stents for SFA lesions 27 of which developed a focal reaction expressed with a ‘halo’ sign on US around the stent. The overall outcomes of the study were satisfactory, and the enhanced reaction appears to be significantly corelated with increased primary patency but without increased complications.
Are you about to submit your paper to CVIR?
Click here to find out which biological/biomedical reporting checklists are mandatory when submitting to CVIR.
CIRSE has a journal family!
Good papers submitted to CVIR and not accepted due to CVIR's limited page budget will be offered transfer to CVIR Endovascular for consideration.
2-year impact factor
5-year impact factor
Downloads in 2022
|Days to first decision (2022 median)